Caspofungin Injection
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 1, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Caspofungin With TMP/SMZ for Moderate-to-Severe PCP in HIV Caspofungin With TMP/SMZ for Moderate-to-Severe PCP in HIV
Is this combination treatment regimen an effective therapeutic option for pneumocystis pneumonia in HIV patients?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 5, 2021 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
Class 4 medicines defect information: Caspofungin 70mg powder for concentrate for solution for infusion
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 drug alert for Caspofungin 70mg powder for concentrate for solution for infusion. Cadiasun Pharma GmBH has advised t (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - September 18, 2018 Category: Drugs & Pharmacology Source Type: news
Three generic forms of caspofungin approved by the FDA
Thu, 03/01/2018 - 12:14News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 1, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Hot Topics in Antifungal Susceptibility Testing: a New Drug, a Bad Bug, Sweeping Caspofungin Testing under the Rug, and Solving the Epidemiological Cutoff Value Shrug
There are several new hot topics in antifungals and antifungal susceptibility testing. In this review, four topics of general interest to the clinical microbiology community are discussed. The first topic is the introduction of isavuconazole, a new triazole approved for clinical use in the United States. The second is triazole resistance in Aspergillus fumigatus isolates. A specific set of mutations are being found with greater frequency in isolates globally, including the U.S. The third topic of interest is a word of caution about antifungal susceptibility testing for caspofungin in Candida isolates; some laboratories hav...
Source: Clinical Microbiology Newsletter - June 18, 2016 Category: Microbiology Authors: Shawn R. Lockhart, Elizabeth L. Berkow Source Type: news
Cancidas (Caspofungin Acetate for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 25, 2016 Category: Drugs & Pharmacology Source Type: news
FDA releases February 2016 510(k) clearances
February 2016 510(k) Clearances
510(k) summaries or 510(k) statements for final decisions rendered during the period February 2016.
TOTAL 510(k)s THIS PERIOD 224
TOTAL WITH SUMMARIES 213
TOTAL WITH STATEMENTS 11
February 2016 510(k) Clearances
510(K) SUMMARIES OR 510(K) STATEMENTS FOR FINAL DECISIONS RENDERED DURING THE PERIOD February 2016
DEVICE: ANI Monitor
MDOLORIS MEDICAL SYSTEMS SAS 510(k) NO: K142969(Traditional)
ATTN: MATHILDE COLLET PHONE NO : 011 333 62092081
6, RUE DU PR LAGUESSE SE DECISION MADE: 23-FEB-16
LILLE FR 59037 510(k) SUMMARY AVAILABLE FROM FDA
DEVICE: DBSWIN and VistaEasy Imaging Software
Durr Dental...
Source: Mass Device - April 5, 2016 Category: Medical Equipment Authors: MassDevice Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news
Posaconazole and Caspofungin Antifungal Susceptibility of Molecularly Confirmed Schizophyllum commune, an Emerging Basidiomycete Fungus
S. Kathuria, P. K. Singh, J. F. Meis, A. Chowdhary (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - September 25, 2013 Category: Respiratory Medicine Source Type: news
Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths
Hall RG 2nd, Swancutt MA, Meek C, Leff R, Gumbo T (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - June 11, 2013 Category: Respiratory Medicine Source Type: news
